12:00 AM
Jun 09, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

KD019: Phase Ib/IIa started

Kadmon began an open-label, U.S. Phase Ib/IIa trial of once-daily oral KD019 in combination with Herceptin trastuzumab every 3 weeks in up to 38 patients with HER2-positive breast cancer who have received prior trastuzumab therapy. The Phase Ib portion, which will...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >